Cytokine and lipid metabolome effects of low-dose acetylsalicylic acid in critically ill patients with systemic inflammation: a pilot, feasibility, multicentre, randomised, placebo-controlled trial.
CONCLUSIONS: In ICU patients with SIRS, low-dose ASA did not significantly alter serum IL-6 concentrations, but it did affect plasma concentrations of certain lipid mediators. The ability to measure lipid mediators in clinical samples and to monitor the effect of ASA on their levels unlocks a potential area of biological investigation in critical care.
TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (ACTRN 12614001165673).
PMID: 32900329 [PubMed - in process]
Source: Critical Care and Resuscitation - Category: Intensive Care Tags: Crit Care Resusc Source Type: research